Protea Biosciences (PRGB) 0.6000 $PRGB
USDA Acquires Protea's LAESI(R) Technology Platform
GlobeNewswire - Wed Sep 24, 7:30AM CDT
Protea Biosciences Group, Inc. (OTCQB
RGB) ("Protea"
announced today that the United States Department of Agriculture (USDA) Agricultural Research Service has purchased Protea's LAESI DP-1000 System for direct molecular analysis. The system will be used by the USDA to identify and screen for mycotoxins in food and feed that can be hazardous to humans and animals.
Protea Biosciences and InSphero AG Enter Into Collaboration and Co-Marketing Agreement to Combine 3D Technologies
GlobeNewswire - Wed Jul 09, 7:30AM CDT
Protea to Apply Direct 3D Molecular Imaging Platform to InSphero's 3D InSight(TM) Microtissues
Protea Announces Presence at 62nd American Society of Mass Spectrometry Annual Conference June 15 - 19, 2014 at the Baltimore Convention Center
GlobeNewswire - Thu Jun 12, 3:00PM CDT
Protea Biosciences Group, Inc. (OTCQB RGB) ("Protea" announced today that it will be attending the American Society of Mass Spectrometry Annual Conference in Baltimore, MD. The Conference will take place at the Baltimore Convention Center, located at 1 West Pratt Street, Baltimore, MD 21201 from Sunday June 15 through Thursday June 19.
Protea to Present at 2014 Needham Healthcare Conference
GlobeNewswire - Tue Apr 01, 9:00AM CDT
Protea Biosciences Group, Inc. ("Protea" announced today that Steve Turner, Protea's CEO, will present at the Needham & Company 13 Annual Healthcare Conference on Tuesday, April 8, 2014 at 11:20 AM, at the Westin Grand Central Hotel in New York City. Mr. Turner will provide a corporate update and will be available for one-on-one meetings with conference attendees.
Protea Announces 2013 Year-End Results and Key Developments
GlobeNewswire - Mon Mar 31, 7:15AM CDT
Protea Biosciences Group, Inc. ("Protea" released its 2013 results today reporting total revenue for the fiscal year ended December 31, 2013 of $1.22 million. This represents a 47% increase over Protea's fiscal year 2012 total revenue and is the first fiscal year that total revenues exceeded $1.0 million. This increase in revenue is the result of sales of the Company's LAESI instrument platform.
USDA Acquires Protea's LAESI(R) Technology Platform
GlobeNewswire - Wed Sep 24, 7:30AM CDT
Protea Biosciences Group, Inc. (OTCQB
RGB) ("Protea" announced today that the United States Department of Agriculture (USDA) Agricultural Research Service has purchased Protea's LAESI DP-1000 System for direct molecular analysis. The system will be used by the USDA to identify and screen for mycotoxins in food and feed that can be hazardous to humans and animals. Protea Biosciences and InSphero AG Enter Into Collaboration and Co-Marketing Agreement to Combine 3D Technologies
GlobeNewswire - Wed Jul 09, 7:30AM CDT
Protea to Apply Direct 3D Molecular Imaging Platform to InSphero's 3D InSight(TM) Microtissues
Protea Announces Presence at 62nd American Society of Mass Spectrometry Annual Conference June 15 - 19, 2014 at the Baltimore Convention Center
GlobeNewswire - Thu Jun 12, 3:00PM CDT
Protea Biosciences Group, Inc. (OTCQB
RGB) ("Protea" announced today that it will be attending the American Society of Mass Spectrometry Annual Conference in Baltimore, MD. The Conference will take place at the Baltimore Convention Center, located at 1 West Pratt Street, Baltimore, MD 21201 from Sunday June 15 through Thursday June 19. Protea to Present at 2014 Needham Healthcare Conference
GlobeNewswire - Tue Apr 01, 9:00AM CDT
Protea Biosciences Group, Inc. ("Protea"
announced today that Steve Turner, Protea's CEO, will present at the Needham & Company 13 Annual Healthcare Conference on Tuesday, April 8, 2014 at 11:20 AM, at the Westin Grand Central Hotel in New York City. Mr. Turner will provide a corporate update and will be available for one-on-one meetings with conference attendees. Protea Announces 2013 Year-End Results and Key Developments
GlobeNewswire - Mon Mar 31, 7:15AM CDT
Protea Biosciences Group, Inc. ("Protea"
released its 2013 results today reporting total revenue for the fiscal year ended December 31, 2013 of $1.22 million. This represents a 47% increase over Protea's fiscal year 2012 total revenue and is the first fiscal year that total revenues exceeded $1.0 million. This increase in revenue is the result of sales of the Company's LAESI instrument platform. 
